Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SuVax
- Development stage
- Preclinical
- Lead developer
- Soligenix
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular (expected Based On Standard Practice For Similar Vaccines; Specific Route Not Explicitly Stated In Sources)
01
Overview
SuVax is a thermostable subunit protein vaccine composed of recombinantly expressed Sudan ebolavirus glycoprotein. It is designed for the prevention and post-exposure prophylaxis of infection caused by Sudan ebolavirus (SUDV), one of the four ebolaviruses known to cause disease in humans. The vaccine utilizes a novel nano-emulsion adjuvant to induce broad immunity and incorporates a proprietary formulation process that enables heat stability, allowing storage at temperatures up to 40°C for at least two years. In nonhuman primate studies, SuVax provided 100% protection against lethal SUDV challenge, with all vaccinated animals surviving and remaining healthy. The recombinant protein manufacturing process and adjuvant used in SuVax have been validated in other clinical-stage subunit vaccines[1][2][3][5].
- Brand names
- SuVax
- Other names
- SuVax
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on SuVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SuVax.